Abstract Details

Title Brain Atrophy as a Non Response Predictor to Interferon ? in Relapsing Remitting Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 191

Objective

Background BACKGROUND: Several predictors for treatment failure to interferon beta (IFN?) have been proposed, however brain atrophy has not been well studied.

Design/Methods DESIGN/METHODS: In this prospective and longitudinal study, all consecutive relapsing-remitting multiple sclerosis (RRMS) patients treated with sc IFN? 1[ordf] where included. Confirmed disability progression or a new relapse between weeks 48 - 144 after IFN? beginning were considered as treatment non response. EDSS progression, relapses, number of active lesions at 1 year (new or enlarging T2-weighted plus gadolinium-enhancing lesions, categorized in >2 or ?2) and brain parenchymal fraction (% BPF) volume change within the initial year of treatment were used as predictive factors. Cox regression model was adjusted for age, gender and disease duration.

Results RESULTS: 71 patients were included (71.8% female) with a follow-up of 144 weeks. 34 (48%) fulfilled criteria of non response to IFN? treatment. The model showed: 1) relapses + disability progression HR=4.6 (p<0.001, IC95% 3.1-6.7); 2) relapses + BPF decrease HR=4.1 (p 0.001, IC95% 3.2-7.3); 3) relapses + disability progression + new active lesions HR=10.1 (p<0.001, IC95% 7.1-15.2) and 4) relapses + disability progression + new active lesions + BPF decrease HR=14.4 (p<0.001, IC 95% 11.4-21.2).

Conclusions CONCLUSIONS: Adding BPF measures to previously described predictive failure factors may increase sensibility to early identify non responder patients to IFN? 1[ordf] in the second and third year of therapy.

Authors/Disclosures
PRESENTER	No disclosure on file
Liliana B. Patrucco, MD (Hospital Italiano De Buenos Aires)	Dr. Patrucco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Patrucco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Patrucco has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Patrucco has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Patty Riley, RN (CSL Behring)	No disclosure on file

��ɫ��

��ɫ��